MDWD

13.5900.37%
OG

Ofer Gonen

Chief Executive Officer

Mr. Ofer Gonen, B.Sc. MA Economic & Finance, serves as Chief Executive Officer at MediWound Ltd. since June 30, 2022. He was Chief Executive Officer of Clal Biotechnology Industries Ltd. from March 7, 2017 to until 2022. He was employed at Clal Biotechnology Industries Ltd. from September 01, 2003 to 2022. He focused on Life Sciences. Mr. Gonen served as an Acting Chief Executive Officer at Clal Biotechnology Industries Ltd. until March 7, 2017 and previously and Interim Chief Executive Officer since November 20, 2015. Mr. Gonen served as a Vice President at Clal Biotechnology Industries Ltd. from September 2003 to November 2015. Mr. Gonen had been with Clal Biotechnology Industries since 2003 and managed life sciences investments, business development, US-based operations and investment support for CBI’s portfolio companies. He was a Partner at ARTE Venture Group Ltd. He served as the Partner of Arta Venture Group Ltd. Prior to joining CBI, Mr. Gonen served as the General Manager of Biomedical Investments as well as a technology consultant to various Israeli venture capital funds and an Academic Aide to the Governor of the Bank of Israel. Mr. Gonen provided consulting services for several leading Israeli venture capital firms. He was Acting Chief Executive Officer and Deputy Chief Executive Officer of Clal Biotechnologies Industries Ltd. He serves as an Executive Board Member of ColBar LifeScience Ltd. TransPharma, Polyheal, BrainTact, Thrombotech, Campus Bio Management Ltd. and Clal Life Sciences L.P. He serves as Chairman of the Board of Directors of Clal Application Centre Ltd. He serves as Chairman at Polyheal Ltd. He served as a Director of MediWound Ltd. since September 2003 until July 2022 and BioCancell Ltd. since November 12, 2015. He served as an Independent Director of Elicio Therapeutics Inc. from April 2021 to September 2022. Mr. Gonen served as Director of Gamida Cell Ltd. from January 2015 to June 9, 2022. He served as a Director of Avraham Pharmaceuticals Ltd. He has been a Director of D-Pharm LTD. since July 15, 2015. He serves as a Director of Vedantra, Mnemosyne, eXIthera, CureTech Ltd. Braintact Ltd. CampusBio Management Ltd. Biokine and Protab. Mr. Gonen gained extensive experience in R&D and management in defense-oriented projects within TALPIOT program of the Israeli Defense Forces, for which he was awarded the Israeli National Security Medal. He served as Chief Executive Officer and Director at Cactus Acquisition Corp. 1 Limited until February 23, 2024. He is a managing Partner at the Anatomy Medical Fund. He served as Director of Arta Venture Group Ltd. He served as a Director at Andromeda Biotech Ltd. He received an M.A. in Economics and Finance, magna cum laude and MS Computer Science, both from the Tel Aviv University and a B.Sc. in Physics, Mathematics and Chemistry, magna cum laude, from the Hebrew University of Jerusalem.

Positions